Loading organizations...
Loading organizations...
Leyden Labs is a technology company.
Leyden Labs develops innovative nasal sprays designed to neutralize respiratory viruses directly at the nasal mucosa. Its core product uses engineered antibodies delivered intranasally, preventing initial infection and onward transmission. This approach harnesses mucosal immunity by targeting broadly protective viral epitopes, inspired by pan-influenza antibodies for enduring protection against diverse viral strains.
Koenraad Wiedhaup, Ronald Brus, and scientific visionary Jaap Goudsmit founded the company, driven by the insight that stopping viral infections at their entry point is crucial. Goudsmit, a renowned scientist, contributed pioneering work on broadly neutralizing antibodies, forming the scientific bedrock for Leyden Labs’ antiviral strategy.
Leyden Labs aims to provide universal, autonomous protection for individuals against current and emerging respiratory viral threats. Its vision centers on accessible, self-administrable products empowering people against a wide range of viruses. The company’s long-term objective is to preemptively safeguard global health from future endemic and pandemic challenges.
Leyden Labs has raised $315.7M across 5 funding rounds.
Leyden Labs has raised $315.7M in total across 5 funding rounds.
Leyden Labs has raised $315.7M in total across 5 funding rounds.
Leyden Labs's investors include Svetoslava Georgieva, Robert de Groot, Khoo Shih, Polaris Partners, F-Prime Capital Partners, David Schenkein, Kleiner Perkins, Qiming Venture Partners, GV, Eli Casdin, ARCH Venture Partners, Arrive.
Leyden Labs is a clinical-stage biotechnology company founded in 2020 and headquartered in Leiden, Netherlands, specializing in intranasal nasal sprays that deliver broadly protective antibodies to block respiratory viruses like influenza and coronaviruses at their entry point in the nasal mucosa.[1][3][4] The company serves healthcare sectors and individuals seeking preventive protection against viral infections, addressing the problem of rapid viral spread and limitations of traditional vaccines by offering self-administrable, non-vaccine solutions that target viral family commonalities for protection against known and emerging strains.[1][2][4][5] With $257M raised to date, including a $70M Series B-II round five months ago and a recent €30M from the European Innovation Council Fund, Leyden Labs demonstrates strong growth momentum, advancing its lead candidate CR9114 (licensed from Janssen) into Phase 1 clinical trials for influenza under the PanFlu program.[1][3][7]
Leyden Labs was founded in 2020 in Leiden, Netherlands—a hub for life sciences inspired by the city's history of scientific breakthroughs like Galileo's work—by co-founder and CEO Koenraad Wiedhaup and Chief Scientific Officer Jaap Goudsmit, whose team discovered CR9114 over a decade ago as the broadest-neutralizing anti-influenza antibody.[3][4][7] The idea emerged from harnessing mucosal immunity and antibody modification for nasal delivery, building on Goudsmit's research published in Frontiers in Virology, to create accessible protection against respiratory threats post-COVID.[4] Early traction came via an exclusive license for CR9114 from Janssen Pharmaceuticals (Johnson & Johnson) and initial investment in 2021 from F-Prime Capital, fueling preclinical success and progression to clinical-stage development.[2][3]
Leyden Labs rides the post-pandemic wave of demand for rapid, broad-spectrum respiratory defenses amid rising influenza and coronavirus threats, where vaccines struggle with variants and deployment speed.[1][3][4] Timing is ideal given Europe's life sciences momentum in Leiden and global funding for deep tech like the EIC Fund's €30M investment, which bridges commercialization gaps for public-benefit innovations.[3] Market forces favoring non-vaccine prophylactics—such as antibody sprays for at-risk populations and pre-exposure protection—align with supply chain resilience needs and lessons from COVID, positioning Leyden to influence biotech by pioneering mucosal antibodies as a new standard.[2][5] As a Series B company with $257M raised, it bolsters the Dutch biotech ecosystem alongside peers like Alesta Therapeutics, accelerating Europe's role in pandemic preparedness.[1][3]
Leyden Labs is poised to advance PanFlu (CR9114) through clinical milestones, potentially yielding the first broadly protective intranasal flu product, with pipeline expansion to other viruses via its platform.[3][4][7] Trends like recurrent flu seasons, variant emergence, and mucosal tech adoption will propel growth, amplified by EU funding and partnerships for scaling manufacturing.[3] Its influence may evolve from niche innovator to ecosystem shaper, enabling self-protection that reduces healthcare burdens and readies humanity for the next threat—transforming Leyden Labs from a 2020 startup into a respiratory defense leader.[1][2][4]
Leyden Labs has raised $315.7M across 5 funding rounds. Most recently, it raised $35.2M Other Equity in October 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 2, 2025 | $35.2M Other Equity | Svetoslava Georgieva | |
| Jun 3, 2025 | $23.5M Debt | Robert de Groot | |
| Jan 1, 2025 | $70.0M Series B | Khoo Shih, Polaris Partners | F-Prime Capital Partners, David Schenkein, Kleiner Perkins, Qiming Venture Partners |
| Jan 1, 2022 | $140.0M Series B | GV, Eli Casdin | ARCH Venture Partners, Arrive, F-Prime Capital Partners, David Schenkein, Krishna Yeshwant, Kleiner Perkins, Menlo Ventures, Yumin Choi, Jeff Bird, Byers Capital, F-Prime Capital, Invus, Vali Barsan |
| Mar 1, 2021 | $47.0M Series A | GV | ARCH Venture Partners, Arrive, F-Prime Capital Partners, David Schenkein, Krishna Yeshwant, Kleiner Perkins, Menlo Ventures, Yumin Choi, Brook Byers, Casdin Capital, Stephen Knight |